Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and atezolizumab monotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Disease-specific inclusion criteria:
General inclusion criteria:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
363 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal